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Background: This study used a standard research approach to create a final conceptual model
and the Preference for the Testosterone Replacement Therapy (P-TRT) instrument.
Methods: A discussion guide was developed from a literature review and expert opinion to
direct one-on-one interviews with participants who used testosterone replacement therapy
and consented to participate in the study. Data from telephone interviews were transcribed
for theme analysis using NVivo 9 qualitative analysis software, analyzed descriptively from
a saturation grid, and used to evaluate men’s P-TRT. Data from cognitive debriefing for five
participants were used to evaluate the final conceptual model and validate the initial P-TRT
instrument.
Results: Item saturation and theme exhaustion was achieved by 58 male participants of mean
age 55.0 ± 10.0 (22–69) years who had used testosterone replacement therapy for a mean of
175.0 ± 299.2 days. The conceptual model was developed from items and themes obtained from
the participant interviews and saturation grid. Items comprising eight dimensions were used for
instrument development, ie, ease of use, effect on libido, product characteristics, physiological
impact, psychological impact, side effects, treatment experience, and preference. Results from
the testosterone replacement therapy preference evaluation provide a detailed insight into why
most men preferred a topical gel product over an injection or patch.
Conclusion: Items and themes relating to use of testosterone replacement therapy were in
concordance with the final conceptual model and 29-item P-TRT instrument. The standard
research approach used in this study produced the P-TRT instrument, which is suitable for
further psychometric development and use in clinical practice.
Keywords: hormones, hypogonadism, outcome assessment, patient preference, testosterone
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The general prevalence of symptomatic hypogonadism is 6%–12% in the United
States.1,2 While prevalence estimates for hypogonadism are higher for elderly
men (5.1%) compared with middle-aged men (2.1%) with low serum testosterone
(ie, ,320 ng/dL, 11 nmol/L),3 data from the Boston Area Community Health Survey
suggest that symptoms of hypogonadism may be experienced by up to 4.7 million
American men aged 30–79 years.4 Aside from the changes that occur as part of the
natural aging process, testosterone levels are influenced by lifestyle (eg, alcohol,
caffeine, tobacco), psychological factors (eg, mood, stress), and comorbidities, such
as obesity, diabetes mellitus, and sleep disorders.5 As men experience reductions in
testosterone levels, patient-reported outcomes such as quality of life and well-being
are also affected.6,7
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Because testosterone contributes to the regulation of
sexual function, mood, muscle mass, liver function, bone
formation, and immune function,8 males who present with
low levels of testosterone (eg, ,320 ng/dL, 11 nmol/L) are
more likely to experience common symptoms associated with
hypogonadism.9,10 These symptoms include fatigue, reduced
sex drive, lack of energy, mood changes, and regression of
secondary sexual characteristics.11 Although decreases in
total testosterone levels of 1%–2% per year are frequently
associated with the aging process,12 recent evidence suggests
that declining testosterone levels can occur independent
of age when lifestyle factors are considered.13 Regardless
of etiology, men’s efforts to seek medical attention for
hypogonadism usually peak when symptoms interfere with
lifestyle, relationships, and sexual activity.
Once a diagnosis of hypogonadism is confirmed by
assessment of total and free testosterone levels, testosterone
replacement therapy is the mainstay of treatment to
address the clinical manifestations of hypogonadism. 14
Recommendations for testosterone therapy can be initiated
with any of the suggested regimens in accordance with
considerations of the patient’s preference, pharmacokinetics
of the testosterone formulation, treatment burden, and cost.15
However, determining which product is preferred by patients
may be challenging, given the number of products currently
on the market and the options for route of administration
(eg, injection, implant, patch, topical, and oral). Given that
physicians consider product characteristics for each delivery
system with respect to outcomes desired by patients, optimal
patient experience with the product selected is most likely to
occur if patient preferences are factored into a physician’s
product choice. Hence there is the need to evaluate patient
preferences for products, which cannot be accomplished
directly because they may be unaware of all the product
choices. Thus, an opportunity to examine patient preferences
regarding testosterone replacement therapy may improve the
interaction between physicians and patients so that physicians
can prescribe a product for testosterone replacement therapy
that is mutually acceptable.
While patient preference studies extend into several
patient-reported outcome areas, including medical care,16
asthma, 17 overactive bladder, 18 insulin delivery, 19 and
testosterone replacement therapy comparing testosterone
injection with the implant,20 a standard data collection
instrument to assess patient preference for testosterone
replacement therapy products has not been developed. Thus,
more information is needed to understand how preference
may be influenced by product characteristics (eg, physical
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qualities, location of application, and duration of use)
associated with product selection. An instrument to evaluate
patient preference for testosterone replacement therapy will
provide physicians with an assessment tool to optimize
adherence with testosterone replacement therapy by aligning
patient preferences with product characteristics.21 For this
study, we used the principles of grounded theory, a type of
qualitative research approach, to create a conceptual model
and develop and validate an instrument to assess patient
Preference for Testosterone Replacement Therapy (P-TRT).

Materials and methods
Conceptualization
In general, we followed the approach suggested in the US
Food and Drug Administration patient-reported outcome
guidance document, which describes the development and
validation of patient-reported outcome measures that could
be used in product labeling, hypothesis testing, and other
endpoint studies.22 To begin the process of conceptualization,
a systematic literature review of testosterone replacement
therapy was conducted in the fall of 2011. Content extracted
from the literature and expert opinion was used to develop
the initial conceptual framework (ie, a graphic depiction
of the relevant measurement concepts and specific domains).
The literature search was conducted using the following key
words: “testosterone replacement”, “treatment experience”,
“patient-reported outcomes”, “topical”, “patch”, “injection”,
and “preference”. Database searches of Medline and PubMed
yielded 125 articles published between 1999 and 2011.
Articles were categorized as testosterone replacement therapy
review, preference or patient-reported outcome research,
compliance, product comparison, or product attributes.
Existing instruments were examined and summarized for
their ability to contribute to the conceptualization process
in ways consistent with current scientific and regulatory
standards as described in the Food and Drug Administration
patient-reported outcome guidance.22 Because of the paucity
of instruments in the testosterone replacement therapy area,
instruments from other areas (eg, dermatology and general
hormone replacement therapy) were evaluated in terms of
their concept coverage (ie, what they measured), development
history, content validity, and psychometric performance.

Qualitative study design
Principles from grounded theory, a qualitative research
approach, were used to transform the proposed conceptual
framework into the final conceptual model for use in
development of a P-TRT instrument. Grounded theory refers
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to a specific methodology on how to get from systematically
collecting data to producing a multivariate conceptual
theory.23 The principles of grounded theory have been used
successfully in health care research to develop conceptual
models and tools to advance our understanding of health
behavior and to improve interaction between physicians
and patients. 24,25 A research design using a grounded
theory approach will generate data that are rich in detail,
thus providing additional insight into social processes (eg,
causes, contexts, contingencies, consequences, covariances,
and conditions) to understand the patterns,26 and to propose
testable relationships between the dimensions that will be
represented by the final conceptual model. In summary,
the aspect of data collection in grounded theory serves as the
nexus to transform the initial conceptual framework into
the final conceptual model, which serves as the foundation
(ie, grounded by the observations from data collection) for
development of a P-TRT instrument.
Using these principles, data collection, interpretation,
and comparison were accomplished in three stages. In
stage one, data were openly collected and coded from oneon-one participant interviews. To conduct the interviews, a
discussion guide was developed from the literature, expert
opinion, and detailed responses from five participants
who agreed to participate in recorded interviews lasting
approximately 1 hour. One-on-one participant interviews
were then conducted using the standard set of questions
from the discussion guide. Researchers elicited and recorded
responses from participants during interview sessions lasting
up to 30 minutes. The discussion guide elicited information
from participants in the full sample regarding age, length
of time using testosterone replacement therapy product(s),
experience with product features, product comparison, and
preference. Throughout the interview process, researchers
were careful not to bias participant responses by mentioning
specific product features or expected outcomes from product
use. All information gleaned from the participant interviews
was transcribed and analyzed qualitatively, entered into a
saturation grid to determine the frequency with which certain
words or phrases were mentioned by participants and used
to evaluate perceived preference.
The saturation grid provides an opportunity for researchers
to examine items and phrases for redundancy, consolidation,
and clarity, to ensure that each item or phrase is represented
independently on the grid. In the second stage, data were
grouped according to themes based on similarities in relationships and patterns within and among the categories identified
in the data.26 At this point, items and their respective themes
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were examined by five experts, including one physician, three
researchers with extensive experience in psychometrics, and
a nurse practitioner with clinical experience in the area of
testosterone replacement therapy. Experts regularly discussed
the degree of congruency between the content extracted from
the literature and the responses provided from participant
interviews. The content and structure of the instrument in
relation to the final conceptual model was discussed, as well
as item wording, interpretation, and relevance to participants
on testosterone replacement therapy.
Once consensus was reached that all possible items
and themes were exhausted, the final stage was to develop
the P-TRT instrument and conduct indepth interviews
as part of the cognitive debriefing process. In addition
to providing evidence of content and face validity, both
participants and researchers engaged in an interactive
process to test the instrument in the designated population.
The purpose of cognitive debriefing was for investigators
to field test the P-TRT instrument and discuss every word,
phrase, and sentence until agreement was reached with
participants concerning clarity, interpretation, wording, and
completeness. All protocols and guides used in the study
were approved by the Massachusetts College of Pharmacy
and Health Sciences, Boston, MA.

Sample
Participants were selected from a mailing list containing
subjects who agreed to participate in research studies
pertaining to testosterone replacement therapy for conditions
associated with a deficiency or absence of endogenous
testosterone. Enrollment via the online manufacturersponsored website was voluntary. Participants were asked
to provide basic demographic information, type of insurance
coverage, and preferred method of contact (eg, email, direct
mail, or telephone). In exchange for their participation,
participants had the option to accept coupons toward their next
purchase of a testosterone replacement therapy product.
Participant enrollment for the US study started in February
2011 and ended in October 2011. When the preference for
testosterone replacement therapy study started in October
2011, the database contained a list of 6627 subjects. Of
those listed, 1092 subjects had a valid name, consent date,
and telephone number listed in the database. Different
geographical areas were well represented throughout the
US mainland. To be included in the study, participants
had to be male, aged . 18 years, have current or previous
experience with a testosterone replacement therapy product,
and be able to receive testosterone replacement therapy

submit your manuscript | www.dovepress.com

Dovepress

633

Dovepress

Szeinbach et al

under the supervision of a physician. To be included in the
preference subanalysis, participants had to use a testosterone
replacement therapy product for more than 1 month and had to
have experience with more than one testosterone replacement
therapy product. As a strategy to maximize the exchange
of information between academic-based investigators and
participants, only those participants who provided telephone
numbers were contacted. Informed consent was obtained from
each participant as they agreed to participate in the study.
Once consent was obtained, participants were deidentified
during the interview process and throughout all analyses.
Thus, investigators were blinded as to the use of specific
products and other attributes by specific participants.

Data analysis
Descriptive data were analyzed using SPSS software (version
17.0 for Windows; SPSS Inc, Chicago, IL). The content of
the participant interviews was transcribed using N-Vivo 9
qualitative analysis software (QSR International, Cambridge,
MA). The transcription process included identification of
recurring definitions and themes throughout the text, which
produced rich descriptions and theoretical explanations of the
concepts under investigation. Participant-mentioned words
and phrases were documented until all themes and thematic
associations with words and phrases were exhausted. To ensure
that saturation occurred, responses from each participant
were compared with responses from other participants to
verify that all possible word combinations used to describe
testosterone replacement therapy and respective themes were
exhausted. Items and phrases from the participant interviews,
including the preference evaluation, were entered into an
Excel spreadsheet (ie, saturation grid; Microsoft, Redmond,
WA) and analyzed descriptively to assess item frequencies
and to determine which themes prevailed. Data entry,
coding, and wording of items and phrases were examined
by at least two researchers and double-checked for accuracy
by a third investigator. Data from cognitive debriefing of
participants by trained male, academic-based researchers
using the final version of the instrument were conducted until
concordance was achieved with respect to item wording, item
interpretation, and relationship to testosterone replacement
therapy experience and product preference.

Results
Participant interviews and preference
study
A total of 489 participants were contacted by telephone
during December 2011. In Table 1, saturation of items and
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Table 1 Sample characteristics of males using testosterone
replacement therapy

Mean age ± SD (range)
Days of TRT therapy ± SD

All participants
n = 58

Preference*
n = 24 (41.4%)

55 ± 10.0 (22–69)
175.5 ± 299.2

55 ± 7.8 (42–68)
299.8 ± 429.9

Note: *Participants using TRT . 1 month; experience with more than one product
formulation or mode of administration.
Abbreviations: SD, standard deviation; TRT, testosterone replacement therapy.

exhaustion of themes was achieved by 58 male participants
of average age 55.0 ± 10.0 (range 22–69) years. Participants
used testosterone replacement therapy for an average of
175.0 ± 299.2 days, with only four participants mentioning
problems with insurance coverage for testosterone replacement
therapy products. From the total of 58 participants, there
were 24 (41.4%) participants who had used a testosterone
replacement therapy product for more than 1 month. These
participants also provided a product comparison in their
testosterone replacement therapy experience or an evaluation
of product preference. The average age of these participants
was 55.0 ± 7.8 (range 42–68) years, with testosterone
replacement therapy use for an average of 299.8 ± 429.9 days.
The data were skewed because two of the participants
used testosterone replacement therapy for 4 and 5 years,
respectively.
Eight themes emerged from qualitative analysis of the
interview data. The first theme, ease of use, encompassed
all topical characteristics associated with testosterone gel
products. Participants preferred a product that was convenient
to use, easy to apply, easy to handle, with accessible
application location, and dried quickly. The second theme
captured libido and included both sex drive and the desire
for a sexual relationship. The third theme related to weight
loss, muscle tone, shape, and exercise, all of which described
the physiological impact of testosterone replacement
therapy. Fourth, the psychological impact was described by
participants as feeling better, having more energy, “feeling
like myself again”, and stamina. The fifth theme contained
items relating to physical product characteristics (eg, texture,
did not stain clothing, not greasy, not sticky, and appearance).
During the interview, some participants described the sixth
theme in terms of side effects, such as rash, irritation, red
blotches, and dry and itchy skin. The seventh theme focused
on the treatment experience, which included several items
and phrases, including pleasing experiences or outcomes,
product worked or helped, expectations were met, and
satisfied with product use. The last theme, preference, was
described as “preferred this product”.
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Saturation grid
The saturation grid contained 45 items and phrases that
captured the content of the participant interviews. The
number of times each item or phrase was mentioned was
recorded directly onto the grid for each participant. The
frequencies were totaled and grouped into major themes
(Table 2). The most salient items and phrases mentioned
by 10% or more of the participants were related to product
convenience, energy and stamina, and sex drive.

conceptual framework. At this stage, the conceptual
framework was examined to ensure that a possible alignment
existed between each item and dimension in the framework.
Once a match was confirmed between items and dimensions,
the items were used to develop the initial 31-item P-TRT
instrument, and the eight dimensions were arranged to form
the final conceptual model. Cognitive debriefing interviews
were conducted to evaluate the final conceptual framework,
which provided a foundation to validate the initial P-TRT.

Preference evaluation

Cognitive debriefing interviews

There were four participants who preferred injections over
topical gels, with one participant preferring both the injection
and topical gel. In situations where testosterone levels were
low or fluctuating, participants perceived that the injections
maintained their levels better, lasted longer, or brought
them into the correct range more efficiently, especially for
participants requiring higher doses of testosterone (Table 3).
One of these participants preferred an injection every 2 weeks
compared with a product that required daily application, while
another participant based his preference on product cost. Two
participants preferred the patch. The quick application and
not having to wash hands were cited as reasons for patch
preference. There were 17 participants who liked or preferred
the gel for reasons attributed to convenience, ease of use, not
staining clothes, more energy, stamina, and increased libido.
However, two participants eventually discontinued product
use because of ineffectiveness. Although complaints about
the topical gel included burning sensation, itching, rash, a
peeled-skin appearance, and drying time, some participants
preferred the topical gel over the injection, citing the
advantages of not having to go to a physician’s office to
receive injections and pain avoidance.
Data from the participant interviews, saturation grid,
and preference evaluation were used to modify the proposed
Table 2 Response rate (%) of participants for major themes of
the saturation grid
Items*

Responses
n = 58, (%)

Ease of use
Energy level
Libido
Odorless or only a slight odor
Fast or quick drying time
Convenience
Feel better
Muscle tone, shape, fat redistribution

56.9
39.7
34.5
22.4
13.8
12.1
10.3
10.1

Note: *Participant mention of the reported items and phrases had to be $10%.
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For the cognitive debriefing interviews, 80 further participants
were contacted to obtain five participants who agreed to
participate in comprehensive interviews using the P-TRT
instrument. These five participants with experience of
testosterone replacement therapy were instructed to think
about testosterone replacement therapy and how each item or
phrase in the instrument would influence their decision to use
testosterone replacement therapy products. Next, participants
were asked to interpret each item in the instrument (eg, item
meaning, clarity, and relevance to testosterone replacement
therapy) to determine the extent of congruency between
participant-provided information and content gleaned from
the literature and expert opinion. Participants were encouraged
to think aloud, provide definitions for certain items, and
discuss the rationale for selecting their responses. In addition,
participants were encouraged to ask questions about any of
the items mentioned or discussed during the interviews.
Once cognitive debriefing was completed, researchers
reviewed the responses and modified the instrument to
improve the wording, clarity, and interpretation. Two items
(ie, ease of use and effectiveness) were considered redundant
and removed, thus reducing the final P-TRT instrument to
29 items (Appendix) and confirming the themes in the final
conceptual model (Figure 1). In the final conceptual model,
participant and product characteristics are hypothesized
to predict libido, psychological and physiological effects,
side effects, and ease of use, which influences the treatment
experience and product preference. To ensure that
participants could make the connection between testosterone
levels (primary patient-reported outcome endpoint measure)
and perceived outcomes such as preference, participants were
asked to recall what their testosterone levels were at the end
of the interview. While only two participants were able to
recall their testosterone levels, the other three participants
understood the importance of testosterone monitoring and
stated it would be easy to obtain this information from their
physicians.
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Table 3 Results for participants using testosterone replacement therapy for more than 1 month and having experience with more
than one product
ID

Age

Days

TRT experience

Comparison

Preferred

Current use

Endpoint

1

48

90

Effective: pleased with product; apply by myself;
no transportation to doctor’s office.

2 other
products

TG

Yes

2

66

120

I

TG

Yes

3

50

270

Effective; pain to put it on everyday;
some burning sensations; wait time to dry.
Positive: Both about the same.

Another TG

TG

Yes

4

54

365

I

TG

Yes

5

46

180

TG and oral
tablets

Patch

Yes

6

64

90

I used another product where I had to do the
injection into the muscle, and the gel is easier
because there is no sticking and blood, etc.
But the injection more potent; lasts longer.
Yes it is the gel, and I apply topically to the inner
thigh and I really can’t really tell if it’s working or
not because I am on so many other meds, can’t tell
any difference.
It worked.

Feel better,
more energy;
convenience
Energy; worked as
well as injections
More energy;
decrease mood
swings
More sex drive;
more energy; but
skin looks like it’s
peeling at times
Patch; quicker;
more convenient

Another TG

TG

7

54

365

Helped as far as my energy level. I don’t know if it
has helped with regard to erectile dysfunction,
I don’t know which part was mental and physical.

Another TG

TG

Switched to
another TG
Yes

8

47

120

Another TG
and I

TG

Discontinued;
TG - high
cost

9

55

365

First I found it very expensive; my insurance didn’t
cover it at all. I did find that it worked fine. I almost
liked it better than the shot; it gave me a normal feel.
The shots really hype you up, puts you almost on a
cocaine buzz.
I don’t use the gel anymore. I didn’t like having to
wash my hands every time.

TG

Patch

Slept better; lost
weight

10

45

113

I and TG

TG

11

68

90

Another TG

TG

Discontinued

No efficacy

12

66

90

Two different
TGs

I

Switched to
injection

Less frequency
with injections

13

61

42

TG

I

Yes

Injection: lower
cost

14

42

90

TG

I

Yes

Injection: better
outcomes

15

57

365

Not effective: I really was expecting like a boost
of energy or some type of extra, sexual stamina/
strength or something. I couldn’t really feel much
of anything.
Not very effective: Ease of use was good, no odor
but it didn’t work very well. Experienced a boost
for a little bit.
I didn’t like it at all. I was rather annoyed with
working with it. Well I didn’t like the time that it
take to dry. And then I was running into rash and
problems with itching. Never saw results with
topical gel.
I put it on. I’m not sure what you want? Don’t know
of any side effects. Personally I think that it’s sub
therapeutic the dose they have me on. I haven’t used
it long enough to get a testosterone level.
Overall I guess it would be a fair experience. Well as
opposed to injections and other products I’ve used,
I guess the gel’s downfall is that you had to wait for
it to dry. It wasn’t a noticeable boost, the boost was
more gradual.
It’s a product that I plan on continue to use. I will be
at the doctor’s office in 3 months in March. The last
time I had a testosterone level check my levels were
at almost a thousand. So I was very pleased with that.

Switched to
a different
product
Discontinued

I

TG

Yes

No pain; ease
of use

Increased
testosterone
Increased energy;
sexual desire;
outcomes about
the same
More natural

No efficacy

(Continued)
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Table 3 (Continued)
ID

Age

Days

TRT experience

Comparison

Preferred

Current use

Endpoint

16

62

1460

Very good. It gives you the energy you need.

Another TG

TG

Yes

17

48

1825

Injection and
patch

TG

Yes

18

59

270

Another
product

TG

Yes

19

45

180

Yes

59

180

2 other
products
Injection

TG

20

Efficacy: Mixed – the gel works and sometimes it
doesn’t. My testosterone level has fluctuated, I had
had better results with injecting myself, but it is a
painful and longer process. Patch leaves giant red
marks; topical gel was less robust than injection.
Well it works very well, it seems to do very well,
I have had it tested for my levels and it seems to
work well.
Overall, it’s decent, it irritates the skin but other
than that it works well.
Good, but it's not where I wanted it. Supposed to
help with erectile dysfunction but it didn’t really help.

Okay with all of
them
Ease of use; more
energy; weight
loss

TG

Plans to
go back to
topical gel

21

57

45

Another TG

TG

Yes

22

46

90

Another TG

I

Switched to
injection

23

61

210

Another TG

TG

Yes

24

59

180

I found that it did not reliably keep my testosterone
levels up. It just didn’t have the same effect as the
other gel. I wasn’t getting the results for sexual drive
and energy.
It was fine for small doses, 2 squirts per leg. But then
my doctor prescribed me to shots because 6 squirts
got to be a lot to rub in.
Well, as compared to the other one it applies much
better. It doesn’t leave the same kind of sticky or
uncomfortable feeling as the other one does. The
overall effect from using it seems to be satisfactory.
I started taking it because I always seemed tired all
the time, when you lose testosterone you lose your
sex drive, and it has improved a little.

Both I and TG

Both

Yes

Improved stamina,
energy, and sex
drive; no odor
Best one so far
More energy;
felt better, but
did not appear
to help erectile
dysfunction
Smooth texture,
odorless, clear,
quick absorption,
no stain
Inconvenience;
needed a larger
dose
Increased energy;
sex drive; no
negative effects
Increased sex
drive and energy

Abbreviations: I, injection; TG, topical gel; TRT, testosterone replacement therapy.

Discussion
This study described the creation of a conceptual model and
a P-TRT instrument that was developed from consistent and
valid responses to assess product preference in participants
with hypogonadism. Using a qualitative research approach
and principles from grounded theory, data extracted from
the literature and expert opinion were used to develop the
initial conceptual framework, which was tested and modified
throughout the data collection process until the final conceptual model emerged prior to cognitive debriefing. Rich data
were obtained from one-on-one interviews with participants,
theme analysis, and preference evaluation. Common words,
phrases, and themes gleaned from the interviews and theme
analysis were supported in the evaluation of preference
regardless of how long testosterone replacement therapy was
used by participants. The P-TRT instrument, developed in
conjunction with the final conceptual model, was validated
from the rich data sources and cognitive debriefing.

Patient Preference and Adherence 2012:6

The P-TRT is the first instrument to offer detailed
information provided by participants regarding testosterone replacement therapy preference with respect to several
dimensions, including ease of use, libido, product characteristics, physiological impact, psychological impact,
side effects, and experience of treatment. In another study
investigating how physicians decided to recommend a new
medicine for either depression or hypertension, three themes,
ie, physician-patient relationship, outside influences (eg,
cost, sales representative), and professional expertise, were
identified to be related to patient beliefs and preferences.27
As perceived by these patients, physicians were recognized
as having the knowledge to recommend specific products that
were the best in a given situation.27 Therefore, it would be
expected that information gleaned from the P-TRT could be
used by physicians to gain knowledge as to how higher-level
personal needs (ie, sex drive and desire, and feeling better)
relate to patient preference. The rationale is that physician
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Libido

Psychological
impact

Patient
characteristics

Product
characteristics

Physiological
impact

Treatment
experience

Preference for
testosterone
replacement
therapy
(P-TRT)
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Figure 1 Final conceptual model for testosterone replacement therapy product preference.

selection and prescribing of products preferred by patients
may be viewed more favorably by them and more likely to
meet their expectations,28 thus improving their adherence29
and the treatment experience.
In addition to development of the P-TRT, another contribution of this study was the creation of a conceptual model
for use in future research. Whereas the initial conceptual
framework specifies a broad taxonomy of patient-focused
outcomes relevant to a given disease or health condition, the
final conceptual model goes one step further by proposing
causal linkages and relationships between these outcomes.30
Cognitive debriefing reinforces the entire process of conceptualization and instrument development by engaging both
researchers and participants in discussions that confirm all
aspects of data collection. A careful examination of data
collected at each juncture ensures that the final conceptual
model is operational in that data collection will lead to
hypothesis testing, theory development, and advances in the
understanding of testosterone replacement therapy product
preference. Thus, the conceptual framework can serve as a
starting point to monitor how physician-based testosterone
replacement therapy product recommendations influence
patient preferences across multiple scenarios (eg, first time
versus experienced testosterone replacement therapy use).
The limitations of qualitative studies primarily focus on
sampling procedures and to some extent data collection.
While the number of participants included in the study was
sufficient to meet the study objectives, it is possible that bias
was introduced by limiting contact to participants with active
telephone numbers. In addition, the sample was purposive
and provided convenient access to participants. Thus, some
individuals not contacted may have different perceptions of
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product preference that were not measured. The one-on-one
interview format conducted by trained, male researchers from
an academic setting was selected to optimize the exchange
of information between participants and researchers. Our
thinking was that participants would feel more comfortable
discussing issues related to testosterone replacement therapy
using a more personal and private format. However, different circumstances (eg, focus groups, email), could produce
different results.
In this study, insurance issues were cited by four
participants. One of these participants was on a co-pay
assistance program and had to pay the difference in cost to
use the preferred topical gel. Another had to switch because
insurance coverage eventually ended after he became
unemployed. The other two participants had to switch from
either a topical gel to another topical gel or injection because
of cost. Although insurance-related issues were limited to
these four participants, preference may be influenced by
other variables, such as insurance benefit design and relative
product costs in tiered co-pay programs. Hence, a potential
selection bias may exist because preference could be driven
by insurance-related issues. Additional research is needed
to understand the impact of various cost and access issues
on product preference.
To participate in the evaluation of preference, participants had to have prior experience of at least one other
testosterone replacement therapy product. Although a
control group was not considered, nine participants who
had used testosterone replacement therapy for less than
1 month had similar expectations regarding sex drive,
energy, and benefits from product ease of use (eg, dries
quickly, no staining, and not sticky). However, as with
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the use of any medication, perceptions of preference may
change as participants evaluate other products having
different formulations or routes of administration. Given
the controlled distribution of products for testosterone
replacement therapy and the important role that physicians
play in recommending testosterone replacement therapy,
future studies are needed to extend development of the
instrument so the results can be applied in clinical practice.
In addition to further assessment of reliability, validity,
and items to test the relative importance of relationships
among the dimensions that are hypothesized to exist in the
final conceptual model, the instrument should be evaluated
under different experimental conditions. Although gels
and long-acting injectable formulations represent the most
modern preparations that can satisfy the criteria for chronic
replacement therapy, 31 most participants in this study
were experienced in the use of topical products based
on the study selection criteria and previous experience.
Nonetheless, some patients selected topical gels over injections for reasons (eg, transportation issues, having to go
to the physician’s office) not related to product features.
Thus, future studies are needed to examine how product
preference and adherence to physician’s recommendations
may be influenced by external factors or how product preferences may contribute to more effective therapy in those
situations. Further, more research is needed to understand
the role of injectable testosterone replacement therapy
products in patient preference and adherence.

Conclusion
In this study, principles from grounded theory were used
to transform the proposed conceptual framework into the
final conceptual model. Items comprising the dimensions
in this model were then used to develop the P-TRT instrument to assess product preference among participants with
symptoms of hypogonadism. The instrument was developed
using a qualitative data-collection approach, which included
collection of rich data to identify consistent themes, evaluate preference, and confirm the final conceptual model. The
P-TRT instrument is suitable for further development and
use in future patient-reported outcome studies involving
testosterone replacement therapy.
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Appendix
Directions: Please either mark or circle the number that best describes to what extent each of the following items influences your
preference for a testosterone replacement product?
Please tell us how each of the following items
influences your preference for a testosterone
replacement product

Not
influential

Somewhat
influential

Influential

Very
influential

Extremely
influential

Location of product application
Drying time when applied to skin
Convenience
No skin rash
Skin not itchy
Impact on muscle tone
Effect on sex drive
Sexual desire
No product odor
Texture is not greasy
Absorption rate
Impact on exercise
Impact on stamina
Impact on others (friends, spouse, partner, family)
Impact on energy levels
Attitude about self
Product does not have to be injected
Product works
Product use met expectations
Liking the product
Weight loss from product use
Feel better
Easy to apply
Not sticky
Prefer this product over other TRT options
Prefer this product over injections
Impact on testosterone levels
No skin irritation from use
No discomfort

1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1

2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2

3
3
3
3
3
3
3
3
3
3
3
3
3
3
3
3
3
3
3
3
3
3
3
3
3
3
3
3
3

4
4
4
4
4
4
4
4
4
4
4
4
4
4
4
4
4
4
4
4
4
4
4
4
4
4
4
4
4

5
5
5
5
5
5
5
5
5
5
5
5
5
5
5
5
5
5
5
5
5
5
5
5
5
5
5
5
5

Abbreviation: TRT, testosterone replacement therapy.
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